Table 2. Comparison of 30-Day Outcomes Among Patients Who Did or Did Not Receive Monoclonal Antibody Treatment for COVID-19.
| Outcome | mAb recipients, No. (%) | Nonrecipients, No. (%) | Point estimate, OR (95% CI) | P value | NNTa |
|---|---|---|---|---|---|
| Among all patients | |||||
| No. of patients | 201 | 280 | |||
| Acute medical visitb | 59 (29.4) | 136 (48.6) | 0.44 (0.29 to 0.66) | <.001 | 6 |
| Emergency department visit only | 24 (11.9) | 16 (5.7) | NA | NA | NA |
| Hospitalizationc | 35 (17.4) | 120 (42.9) | 0.28 (0.18 to 0.44) | <.001 | 4 |
| Transfer to outside facility for higher-level care | 4 (2.0) | 26 (9.3) | 0.20 (0.05 to 0.59) | .001 | 14 |
| Intensive care unit admission | 0 | 12 (4.3) | −4.3 (−6.7 to −1.9)d | .003 | 24 |
| Death | 0 | 8 (2.9)c | −2.9 (−4.8 to −0.9)d | .008 | 35 |
| Adverse reaction | 1 (0.5) | NA | NA | NA | NA |
| Among hospitalized patients | |||||
| No. of patients | 35 | 120 | |||
| Symptom duration at admission, No./total No. (%) | |||||
| Asymptomatic | 2/35 (6) | 5/120 (4) | 1.4 (0.13 to 9) | .66 | NA |
| Days, median (IQR)e | 6 (3-9) | 5 (3-8) | .66 | NA | |
| Admission in ≤3 de | 10/32 (31) | 35/108 (32) | 0.95 (0.36 to 2.4) | .90 | NA |
| Days in hospital, median (IQR) | 4 (3-5) | 4 (4-5) | .48 | NA | |
| Oxygen requirement, No./total No. (%) | 26/35 (74) | 91 (76) | 0.92 (0.36 to 2.5) | .53 | NA |
| None | 9/35 (26) | 29/120 (24) | NA | .54 | NA |
| Low flow | 25/35 (71) | 81/120 (68) | |||
| NRB mask, high flow, or BiPAP | 1/35 (3) | 4/120 (3) | |||
| Intubation | 0/35 | 6/120 (5) | |||
Abbreviations: BiPAP, bilevel positive airway pressure; IQR, interquartile range; mAb, monoclonal antibody; NA, not applicable; NNT, number needed to treat; NRB, nonrebreather; OR, odds ratio.
a
Number needed to treat to prevent the given medical outcome. Only given if P < .05.
b
COVID-19–related emergency department visit or hospitalization.
c
COVID-19–related hospitalization, including local hospitalizations and transfers.
d
Absolute risk reductions are given as percentages when ORs were not possible.
e
Among patients with known symptom onset dates (32 mAb-treated patients and 108 nontreated patients).